{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:54:39Z","timestamp":1790646879801,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00595-024-02912-z","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T04:02:07Z","timestamp":1723521727000},"page":"351-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers"],"prefix":"10.1007","volume":"55","author":[{"given":"Hisashi","family":"Kosaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Ikeura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Sekimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kaibori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2912_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ags3.12266","volume":"3","author":"S Matsukuma","year":"2019","unstructured":"Matsukuma S, Tokumitsu Y, Shindo Y, Matsui H, Nagano H. Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg. 2019;3:378\u201389.","journal-title":"Ann Gastroenterol Surg"},{"key":"2912_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/01.sla.0000201482.11876.14","volume":"243","author":"M Nagino","year":"2006","unstructured":"Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364\u201372.","journal-title":"Ann Surg"},{"key":"2912_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00534-009-0205-4","volume":"17","author":"FG Rocha","year":"2010","unstructured":"Rocha FG, Matsuo K, Blumgart LH, Jarnagin WR. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepatobiliary Pancreat Sci. 2010;17:490\u20136.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2912_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"2912_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469\u201374.","journal-title":"Br J Cancer"},{"key":"2912_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jhbp.1288","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, Sakai D. Randomized phase III study of gemcitabine, cisplatin plus 1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA). J Hepato-Biliary Pancreat Sci. 2023;30:1\u20139.","journal-title":"J Hepato-Biliary Pancreat Sci"},{"key":"2912_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jhbp.870","volume":"28","author":"M Nagino","year":"2021","unstructured":"Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition. J Hepatobiliary Pancreat Sci. 2021;28:26\u201354.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2912_CR8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-015-4768-9","volume":"22","author":"A Kato","year":"2015","unstructured":"Kato A, Shimizu H, Ohtsuka M, Yoshitomi H, Furukawa K, Takayashiki T, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22:1093\u20139.","journal-title":"Ann Surg Oncol"},{"key":"2912_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00595-020-02031-5","volume":"50","author":"T Noji","year":"2020","unstructured":"Noji T, Nagayama M, Imai K, Kawamoto Y, Kuwatani M, Imamura M, et al. Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study. Surg Today. 2020;50:1409\u201317. https:\/\/doi.org\/10.1007\/s00595-020-02031-5.","journal-title":"Surg Today"},{"key":"2912_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jhbp.833","volume":"28","author":"Y Sunagawa","year":"2021","unstructured":"Sunagawa Y, Yamada S, Kato Y, Sonohara F, Takami H, Inokawa Y, et al. Perioperative assessment of indocyanine green elimination rate accurately predicts postoperative liver failure in patients undergoing hepatectomy. J Hepatobiliary Pancreat Sci. 2021;28:86\u201394.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2912_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/SLA.0000000000005103","volume":"274","author":"M Mueller","year":"2021","unstructured":"Mueller M, Breuer E, Mizuno T, Bartsch F, Ratti F, Benzing C, et al. Perihilar cholangiocarcinoma \u2013 novel benchmark values for surgical and oncological outcomes from 24 expert centers. Ann Surg. 2021;274:780\u20138.","journal-title":"Ann Surg"},{"key":"2912_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/SLA.0000000000004322","volume":"275","author":"T Mizuno","year":"2022","unstructured":"Mizuno T, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, et al. Combined vascular resection for locally advanced perihilar cholangiocarcinoma. Ann Surg. 2022;275:382\u201390.","journal-title":"Ann Surg"},{"key":"2912_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:1\u201311.","journal-title":"NEJM Evid"},{"key":"2912_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"2912_CR15","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.21873\/anticanres.15887","volume":"42","author":"M Ju","year":"2022","unstructured":"Ju M, Aoyama T, Komori K, Tamagawa H, Tamagawa A, Maezawa Y, et al. The albumin\u2013bilirubin score is a prognostic factor for gastric cancer patients who receive curative treatment. Anticancer Res. 2022;42:3929\u201335.","journal-title":"Anticancer Res"},{"key":"2912_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5230\/jgc.2019.19.e15","volume":"19","author":"T Miwa","year":"2019","unstructured":"Miwa T, Kanda M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, et al. Albumin-bilirubin score predicts tolerability to adjuvant S-1 monotherapy after curative gastrectomy. J Gastric Cancer. 2019;19:183\u201392.","journal-title":"J Gastric Cancer"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-024-02912-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-024-02912-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-024-02912-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:46:38Z","timestamp":1740037598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-024-02912-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2912"],"URL":"https:\/\/doi.org\/10.1007\/s00595-024-02912-z","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board of Kansai Medical University (Approval number: 2021199). It was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}